A Phase 2 clinical trial has been initiated to investigate the effectiveness of ebribafusp in treating IgA nephropathy, lupus nephritis, and C3 glomerulopathy. This trial is an open-label study aimed at assessing the potential benefits of ebribafusp in these conditions. The trial aims to enroll approximately 100 participants with these kidney diseases to evaluate the drug's efficacy and safety.Ebribafusp is a novel treatment approach that shows promise in targeting these specific kidney disorders.